Skip to content

Omnicell

US · OMCL #2961 by market cap Listed 1970
32.51 -0.67 -2.02%
Periodic snapshot; not a real-time feed. · 2026-11-20 20:02

Valuation each multiple against its own 5-year range

P/B ratio 1.22 Cheap vs history 23rd percentile
5-year average 2.23 · #13 of 38 in Health Information Services
P/E ratio 36.49 In line with history 35th percentile
5-year average 69.74 · forward 36.52 · #4 of 16 in Health Information Services
P/S ratio 1.30 Cheap vs history 24th percentile
5-year average 2.21 · forward 1.32 · #19 of 42 in Health Information Services

Vs. peers Health Information Services

Company Market cap P/E (TTM) P/B Div yield
Omnicell (OMCL) 1.50B 33.86 1.14 0.00%
Veeva Systems (VEEV) 43.10B 43.64 5.80 0.00%
BrightSpring Health Services (BTSG) 12.50B 33.78 5.75 0.00%
Tempus AI (TEM) 9.86B -50.98 19.70 0.00%
Hinge Health (HNGE) 8.60B 51.68 28.71 0.00%
HealthEquity (HQY) 7.84B 34.21 3.94 0.00%

Other StockVane-tracked companies in the same industry.

Morningstar

★★★★☆ Fair value39.54 Economic moatNone UncertaintyLow

Trading 21.6% below Morningstar's fair value estimate.

Fair value

Omnicell Inc receives a 4-star quantitative star rating, reflecting our opinion that this share class offers a somewhat attractive opportunity for investors. The stock currently trades at a 11% discount to our quantitative fair value estimate of $39.54 per share, which is reinforced by this estimate's low uncertainty rating.

The firm's valuation metrics increase our estimated fair value. A company's valuation metrics provide insights into the market's expectations for its future growth and profitability. Reflecting the firm's valuation is its book value yield of 76.7%, which lies in the top 45% compared with global peers. The market price is low relative to the book (accounting) value of the company's equity, which contributes to our view that shares are undervalued.

Alternatively, the company's liquidity is potentially concerning. Excessive liquidity may suggest inefficient capital use or limited investment opportunities. The firm's median trading volume over the past 60 days, a core component of liquidity, sits in the top 40% compared with global peers. High trading volumes could indicate a sharp change in business model or a new growth trajectory of the business. Despite our favorable price/fair value ratio, this characteristic is a negative attribute.

Economic moat

The company's quantitative economic moat rating of none suggests any excess returns could erode quickly as competition arrives. Additionally, the firm's moderate financial health score suggests it is acceptably positioned against adverse economic circumstances.

By Quantitative Equity Report

Quote time 2026-11-20 20:02:40 · For reference only, not investment advice and not tailored to your situation.

Omnicell discussion 0 comments

Add a comment